BGB-11417 Alone or in Combination with Zanubrutinib Shows Early Efficacy in CLL/SLL
BGB-11417, when given alone or in combination with zanubrutinib, elicited encouraging responses and minimal residual disease negativity rates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to preliminary data from a phase 1 trial.
HD-ASCT Demonstrates Improved PFS Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma
December 13th 2022Consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation improved progression-free survival vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.
Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.
Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia
December 13th 2022Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
Treatment with zanubrutinib (Brukinsa) reduced the risk of progression or death by 35% compared with ibrutinib (Imbruvica) for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Blinatumomab/Consolidation Chemo Combo Improves OS in MRD-Negative B-cell ALL
Blinatumomab followed by consolidation chemotherapy led to a 58% reduction in the risk of death compared with standard consolidation chemotherapy alone in adult patients with newly diagnosed minimal residual disease–negative B-cell acute lymphoblastic leukemia.
Momelotinib Responses Upheld Through 48 Weeks in Patients With Anemic Myelofibrosis
Momelotinib elicited durable symptom, transfusion independence, and splenic responses through 48 weeks of treatment in patients with myelofibrosis who have anemia and previously received a JAK inhibitor.
Mosunetuzumab Elicits Long-Term Responses in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab demonstrated durable responses and a low rate of adverse events linked with treatment discontinuation in patients with relapsed/refractory follicular lymphoma, according to an updated analysis of the pivotal phase 2 GO29781 study.
Dr Abramson on the Efficacy of Second-line Liso-cel Vs SOC in Relapsed/Refractory LBCL
December 12th 2022Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.
Liso-Cel Second-Line Superiority to Standard of Care Confirmed in LBCL
Second-line treatment with lisocabtagene maraleucel (liso-cel; Breyanzi) reduced the risk of an event occurring by 64.4% compared with standard-of-care chemoimmunotherapy induction and autologous stem cell transplantation for patients with high-risk relapsed/refractory large B-cell lymphoma.
Ibrutinib Induction/Maintenance Is Highly Effective for MCL
The addition of ibrutinib to standard chemoimmunotherapy induction followed by autologous stem cell transplantation (ASCT) and 2 years of maintenance ibrutinib significantly improved outcomes vs standard chemoimmunotherapy induction and ASCT alone for younger patients with mantle cell lymphoma.